TIMP3 and central nervous system cancer: Upregulation of metalloproteinase inhibitor 3 (TIMP3) and inhibition of the PI3K/ACT signalling pathway and knockdown of MIF resulted in a significant increase in susceptivity of drug‐resistant glioma cells to TMZ.